INSMED (IM8N BE) stock market data APIs
€124.149
0(0%)
as of March 18, 2026
Try our APIs with
free plan!
INSMED Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for IM8N.BE.
Prev. Close
124.149
Open
124.149
High
124.149
Low
124.149
52 wk Range
55-180
Market Cap
2 766 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get INSMED data using free add-ons & libraries
Get INSMED Fundamental Data
INSMED Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
INSMED News
New
Insmed Incorporated (INSM) Enters 2026 With Momentum
Insmed Incorporated (NASDAQ:INSM) is among the 10 Unstoppable Stocks to Buy and Hold for the Next 3 Years.Insmed Incorporated (INSM) Enters 2026 With Momentum Insmed Incorporated (NASDAQ:INSM) is o...
Why Insmed Incorporated (INSM) is One of the Best Strong Buy Healthcare Stocks to Invest In
Insmed Incorporated (NASDAQ:INSM) is one of the best strong buy healthcare stocks to invest in. Mizuho cut the price target on Insmed Incorporated (NASDAQ:INSM) to $204 from $211 on February 24, maint...
Insmed (INSM) Is Up 6.9% After BRINSUPRI Sales Beat Expectations And 2026 Target Set - What's Changed
In February 2026, Insmed reported a wider quarterly and full-year loss, with full-year net loss reaching US$1,276.78 million and basic loss per share from continuing operations at US$6.42. At the same...
Insmed Q4 Reinforces Confidence in Brinsupri Growth, RBC Says
Insmed's (INSM) Q4 update supports confidence in the launch trajectory of Brinsupri and provides gre PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
